Abstract Rituximab-induced B-cell depletion has been proven to be a useful therapy for autoimmune hemolytic anemia (AIHA). The aim of this retrospective study was to evaluate the effectiveness of rituximab in the treatment of 36 patients with AIHA refractory to several treatments. These patients had received a median of four (one to eight) previous treatments, and 13 patients had undergone splenectomy. Rituximab was administered by intravenous infusion at a dose of 375 mg/m 2 once weekly for four doses in 29 patients, and 7 patients received one to six doses. Overall, 28 (77%) of 36 patients achieved response. Twenty-two patients (61%) reached a complete response (CR), and 6 patients (16%) obtained a partial response. All patients that reached CR (61%) were able to maintain the response during more than 6 months, with a median follow-up of 14 months (1-86 months). Sixteen patients maintained response for more than 1 year. The predictors of maintained response were achievement of CR and negative Coombs test result. Splenectomized patients showed a better response rate than those nonsplenectomized. Rituximab was well tolerated, and only one patient presented a transitory rash during infusion. Rituximab induced clinical responses in multitreated severe refractory both warm and cold AIHA patients with little toxicity, and consequently, this therapy should be considered as an early therapeutic option in this setting.
Introduction
Autoimmune hemolytic anemia (AIHA) is a disorder in which IgG and/or IgM autoantibodies are directed against autologous red blood cells (RBCs) surface antigens and initiate RBC destruction by the reticuloendothelial system and complement system, respectively. About 80% of patients who suffer from AIHA have warm-reactive antibodies of the IgG isotype; the remainder exhibit coldreactive autoantibodies. Although AIHA can be idiopathic, 20%-80% of patients have a suspected secondary cause such as lymphoproliferative disorders (LDs), autoimmune disorders (ADs), and infections [1] .
In patients with warm AIHA (WAIHA) requiring treatment, corticosteroids represent the first-line therapy, even though only 15%-20% of new cases achieve a complete remision [1] . For those patients initially unresponsive to corticosteroids, the second-line therapy is usually splenectomy, which is associated with an initial response rate of approximately 50% [2] . Treatment options for patients who fail to respond, relapse, or are unable to undergo splenectomy are limited. Citotoxic and immunosuppresant drugs, such as cyclophosphamide, azathioprine, and ciclosporine A, provide a 40%-60% response rate. However, these treatments may be associated with serious side effects. The effectiveness of other options, such us intravenous immunoglobulin, plasmapheresis, and danazol, is controversial [1] [2] [3] .
In patients with cold AIHA (CAIHA), therapy based on corticosteroids is generally not helpful and splenectomy is not usually effective, as complement-coated RBC is mainly destroyed in the liver [4] . In cases with severe hemolysis, immunosuppression with chlorambucil or cyclophosphamide may be beneficial and plasmapheresis can provide transitory improvement. Nevertheless, this therapy is generally unsatisfactory [1, 2, 4] .
The etiology of autoantibody production is not well understood but is thought to involve a complex dysfunction of the immune system and immune surveillance mechanism [5] . Despite the complex pathogenic mechanism of AIHA, B cells play a crucial role in the pathogenesis of these disorders [6] .
Rituximab is a humanized chimeric anti-CD20 monoclonal antibody specific for the CD20 antigen expressed on all normal and malignant mature B lymphocytes. After introduction of rituximab as a powerful therapeutic agent in B-cell non-Hodgkin's lymphoma, numerous attempts have been made to use B-lymphocyte depletion induced by rituximab for the treatment of both nonhematological and hematological autoimmune diseases [4, [6] [7] [8] .
Similar to other autoimmune cytopenias, AIHA is a rare disease, which estimated incidence is 1-3 cases per 100,000 per year [1] , making it difficult to perform randomized trials. Up to now, nonrandomized prospective studies are relatively few, and restrospective series of consecutive patients are often small [9] . An overview of studies including five or more patients reveals that rituximab is effective in treating warm and cold AIHA, with an overall response rate ranging from 40% to 100% (median, 60%) and with patients of all ages responding [4] . Therefore, controlled studies that include larger numbers of patients that have received several treatments in different clinical situations (associated diseases, splenectomy or not) are necessary to asses the role of rituximab in the treatment of adult patients with refractory and severe AIHA.
In the present study, we show the results of a retrospective multicentric Spanish study designed to asses the therapeutic efficacy and toxicity of rituximab in refractory and severe AIHA patients unresponsive to several treatments.
Design and methods
Our group has performed a restrospective multicentric analysis of adult patients with AIHA treated with rituximab between April 2001 and June 2007 in 21 centers in Spain.
Inclusion criteria
In the present study, we have included adult patients with AIHA, both idiopathic AIHA and associated with LD and AD.
Diagnosis of AIHA was based on laboratory evidence of hemolysis (increased reticulocyte count with increased indirect bilirubin, lactate dehydrogenase, or absent haptoglobin levels) and a positive Coombs test.
Refractory and severe AIHA patients were eligible for treatment with rituximab. We defined as refractory AIHA those patients with hemoglobin levels <11 g/dL prior to rituximab treatment who had received at least two therapy lines and patients with hemoglobin levels >11 g/dL prior to rituximab who had received at least three therapy lines and with treatment dependence to maintain this level of hemoglobin before rituximab initiation. All patients were negative for hepatitis B virus (HBV) and hepatitis C virus (HCV). All patients gave informed consent to receive the rituximab under off-label conditions. This study was approved by the local ethics committee, and informed consent for analysing patients' data was obtained.
Treatment
Patients received a weekly dose of 375 mg/m 2 rituximab (Mabthera; Roche Farma, Spain) intravenously for 4 consecutive weeks. During the initial period, 26 multitransfused patients with severe anemia and/or requiring a maintenance dose of therapy received rituximab associated with other therapies as follows: corticosteroids (9 of 26 patients), corticosteroids and cyclosphosphamide (6 of 26 patients), corticosteroids and other treatments they were previously receiving (8 of 26 patients), and other treatments (2 of 26 patients).
Response criteria
The response criteria were defined as follows: complete response (CR), nontransfused hemoglobin level >12 g/dL and hemoglobin increase of at least >2 g/dL above their pretreatment hemoglobin level with the discontinuation of concomitant immunosuppressive therapies; partial response (PR), nontransfused hemoglobin level >10 g/dL and hemoglobin increase of at least 2 g/dL above their pretreatment hemoglobin levels. Maintained response (MR) was defined as the maintenance of response for more than 6 months after the beginning of treatment and with the discontinuation of concomitant immunosuppressive therapy.
Statistical analysis
Analysis of the data was primarily descriptive, using percentages, mean values and standard deviations, medians, and ranges as required. Chi-squared test was used to compare proportions and Student's t test to compare means. We have also represented the results with graph bars including means and 95% confidence intervals (CIs) and box plots with percentiles and extreme values.
A Kaplan-Meier analysis was performed to represent probability of maintaining response in patients and in order to estimate the median and mean of MR. The event considerate to perform this analysis was losing MR, and we censured those patients who had reached the end point of maintenance of response. We use the KaplanMeier program contained in SPSS ver 13.0 (SPSS, Chicago, IL).
Results
We analyzed 36 adult patients with AIHA, both idiopathic AIHA and associated with LD and AD.
Pretreatment characteristics
Patients´demographics and clinical characteristics are summarized in Table 1 .
Prior to rituximab, 31 patients had received three or more treatments, with a median of 4 (range 1-8). The previous treatment included corticosteroids (97%); cyclophosphamide (47%); intravenous immunoglobulin (42%); cyclosporine (28%), azathioprine (14%) and chlorambucil (11%).
Splenectomized patients had received a median of five treatments before rituximab; 77.8% of the patients (28 of 36) had been transfused.
We have also included five multitransfused patients with severe AIHA that showed hemoglobin levels less than 8 g/dL (median hemoglobin levels of 6 g/dL; range, 4-8 g/dL), prior to rituximab, and who had received one therapy line, either corticosteroids (including high dose, four patients) or cyclosporine before receiving rituximab.
Overall, 80.5% (29 of 36) of patients received four doses of rituximab, and 19.5% (7 of 36) of patients received between one and six doses of rituximab (one patient, one, five, and six doses each; two patients, two and three doses each). Response to treatment and its characteristics
The overall response rate for patients receiving rituximab was 77%. Twenty-two patients (61%) achieved CR and 6 patients (16%) obtained PR (Fig. 1) . A large proportion of responses took place between the first and third week of treatment (82% of the responders, 18 patients). The median time to have a response was 3 weeks (range, 1-8 weeks). We also found late responses in five patients between 6 and 8 weeks (Fig. 2) .
Maximum response was achieved after a median time of 10 weeks (range, 4-35 weeks), with median hemoglobin levels of 13 g/dL (range, 10-15.6 g/dL). The increase of hemoglobin levels since pretreatment conditions was statistically significant (p<0.001; Fig. 3 ).
All patients with PR showed an increase of hemoglobin more than 3 g/dL above their pretreatment hemoglobin levels, with a median increase of hemoglobin posttreatment of 5 g/dL (range, 3-7.5 g/dL), a median hemoglobin posttreatment of 10.8 g/dL (range, 10-11.7 g/dL), and a median duration of response of 4 months (range, 1-9 months).
Response maintenance Overall, response was maintained in all the patients that had reached CR (61%; 22 of 36), with a median duration of response of 19 months (range, 6-86 months), and 16 patients were able to maintain the response even more than a year with a median duration of 23 months (Fig. 1) .
In Kaplan-Meier analysis, the estimated mean of MR over the study period was 65.9 months (95% CI, 52.9-78.9). The estimated probability of maintaining response between 6 and 83 months was estimated around 75%. At the end of the study period, median of MR was not achieved. We censured those patients who had maintained response. It must be taken into account that the estimated mean of MR obtained by Kaplan-Meier must be assumed with caution as patients who had maintained their response for the longest periods of time were censured (Fig. 4 ).
Factors associated with response
There were no differences in the response rate between patients with warm (CR and MR 61.5%; 16 of 26) or CAIHA (CR and MR 66.7%; 6 of 9; p=0.9). Moreover, the duration of MR was not significantly different between WAIHA patients (median, 15 months; range, 6-86 months) and CAIHA patients (median, 21 months; range, 17-36 months; p=0.62).
We did not find noteworthy statistical differences in CR and MR rates and duration of response between patients with idiopathic AIHA or those with AIHA associated to LD, AD, allogenic stem cell, and liver transplant. Fifty percent (7 of 14) of patients with idiopathic AIHA and 69% (11 of 16) of patients with AIHA associated to LD experienced CR. We found nonsignificant differences Fig. 2 Timing of response to rituximab therapy. Most of the responses took place between the first and third week (18 patients; 82% of the responders). Only five patients responded between 6 and 8 weeks Fig. 3 Evolution of hemoglobin levels. Median of hemoglobin level prior to treatment was 7 g/dL, and at maximum response, median hemoglobin level was 13 g/dL. There was a significant increase of hemoglobin levels since pretreatment conditions (p<0.001) Fig. 1 Response to rituximab therapy. Twenty-two patients achieved CR (61%) and 6 patients obtained PR (16%). The response was maintained (MR) in all patients who achieved CR, with a median duration of 19 months between both groups in CR and MR (p=0.5) and duration of response (21 and 14 months; idiopathic disease and AIHA associated to LD, respectively; p=0.73). Two of 4 patients with CAIHA associated to LD reached CR, and all of them were to able maintained it, with a median duration of response of 19 and 29 months, respectively.
Most of patients who had maintained response reached a negative result from Coombs test (83.3%; 15 of 18). The frequency of patients who achieved a MR and showed a negative Coombs test was significantly higher than the percentage of patients with a MR but whose result from Coombs test was positive (p=0.017). On the other hand, we did not found significant differences when we compared the duration of response between these subpopulations of patients (15 and 28 months, negative and positive Coombs test, respectively; p=0.65; Fig. 5 ).
Splenectomized patients with WAIHA showed a trend to an enhanced response rate comparing with nonsplenectomized patients, but this difference was not statistically significant (p=0.3). Seventy-five percent of splenectomized patients (9 of 13) achieved a CR that was maintained for a median of 21 months, and 54% (13 of 24) of nonsplenectomized patients showed a CR that was maintained during a median of 19 months. No differences were found in the length of MR regarding splenectomy (p=0.67). Moreover, we did not found remarkable differences either in CR or MR when we analyzed the responses to rituximab in splenectomized or nonsplenectomized patients with CAIHA. Nevertheless, it is worth noting that all splenectomized patients with CAIHA treated with rituximab achieved CR in relation to less than a half of nonsplenectomized (100% and 50%; splenectomized and nonsplenectomized patients, respectively; p=0.53). Furthermore, no differences were found in duration of MR between these groups.
Rituximab therapy alone achieved a CR rate similar to that showed by rituximab in combination with other therapies (60% and 58%; monotherapy and combined therapy, respectively; p=0.8). Moreover, duration of MR between this subsets of patients was comparable (18 and 20 months, respectively; p=0.6). Six patients with WAIHA received rituximab in combination with cyclophosphamide and steroids. Five of these patients suffered from AIHAassociated LD, and they had also received corticosteroids. Four (80%) of these patients achieved CR and were able to maintain this response with a median of duration of 13 months (range, 6-19 months).
Heavily treated patients before rituximab therapy (more than four treatments, including any corticosteroid) did not present significant differences in terms of response rate than those receiving fewer treatments (CR and MR 54.5% and 64.3%; p=0.81). Similarly, both groups maintained the response during a median of 19 months.
The median time from diagnosis of AIHA to rituximab treatment was 8.7 months. Our findings showed no significant differences in the CR and the maintenance of response between the patients with longer duration of AIHA (>8 months) and patients with AIHA lasting less than 8 months before rituximab therapy (55.6% and 61%, respectively; p=1). The median duration of response between these groups did not show notable differences (20 and 15.5 months, respectively; p=0.7).
Age and gender did not seem to influence response to rituximab therapy (data not shown).
Toxicity, side effects, and infectious complications
The treatment was generally well tolerated. All patients were pretreated with acetaminophen, diphenhydramine, and 
Discussion
This study aimed to describe the characteristics of response to rituximab in 36 patients with refractory AIHA both idiopathic and associated with AD or LD. Up to now, rituximab had been shown to be effective for the treatment of refractory AIHA in children and in a small number of adults [10, 11] . Our findings show that rituximab induces a clinically significant response in patients with AIHA who are unresponsive to other therapeutic options. Overall, response rate for patients receiving rituximab was 77%. Sixty-one percent of patients achieved CR, and all of them were able to maintain it. Moreover, this response is not influenced either by gender or age of the patient or by hemoglobin levels prior to treatment in contrast to other reports [12, 13] .
To our knowledge, this study includes the largest series reported to date about the use of rituximab in adults with severe refractory AIHA [4] . Similar findings were obtained in a recent retrospective study including 27 patients with idiopathic or secondary WAIHA [14] , in which rituximab led to an initial response in 25 (93%) cases, with a CR in 8 (30%) and PR in 17 (63%) patients. Three patients were retreated with rituximab, and the same pattern of response (1 CR, 2 PR) was obtained. In our series, only one patient was retreated after maintaining the response during 11 months. This patient reached a new CR with 2 doses of rituximab, which was sustained with rituximab every 3 months.
The therapeutic objective of rituximab therapy in refractory AIHA must be achieve CR, and furthermore, the CR could be consider as a predictor of MR seeing that all the patients with a CR were able to maintain their response. Although to date, no laboratory parameters predictive of response have been identified [15, 16] , our results show that a negative result from Coombs test after rituximab administration could be a factor associated to the maintenance of response. The negative result from Coombs test after treatment seems to be an adequate laboratory predictor of maintenance of response, seeing that 83.3% of patients who had achieved CR showed a negative result from Coombs test and they were able to maintain the response for a median of 15 months.
Regarding splenectomy, both splenectomized and nonsplenectomized patients have obtained a remarkable response, with a trend to a higher response rate in splenectomized patients with WAIHA. It has been previously reported that about 60% of patients who undergo splenectomy achieve a complete remission [3, 17, 18] .
Patients with CAIHA behaved equally in terms of response whether or not they had been previously splenectomized. Besides, it is worth noting that all splenectomized patients with CAIHA treated with rituximab achieved CR in relation to less than a half of those nonsplenectomized who were able to experience a CR. However, splenectomy did not show an effect on response maintenance either in warm or CAIHA patients in our study. These findings could support the hypothesis that an intact spleen is not necessary to achieve a response when patients are treated with rituximab in contrast to other studies particularly in ITP [19] . Moreover, previous splenectomy in AIHA patients could favor the response to immunosuppressant agents. In fact, rituximab has demonstrated to be more effective in patients with AIHA refractory to splenectomy, providing a therapeutic alternative to the prolonged administration of immunosuppressant agents.
The etiology of autoantibodies of AIHA did not influence response to treatment, seeing that there were no statistical differences in response rate and duration of response between patients with warm and CAIHA. Although MR rates obtained in treatment of CAIHA have been generally lower than those reported for the management of warm-antibody disease [20] , the present study shows that rituximab could be effective in obtaining MR in patients with CAIHA, offering an additional treatment choice to this group with limited options.
The present study also includes cases of refractory AIHA secondary to a range of conditions including AD, LD, allogenic stem cell, and liver transplant, which have been excluded in other reports [13, 21] . We did not find statistically significant differences in CR, MR rate, and duration of response between these patients and those with idiopathic refractory AIHA. These data suggest that rituximab could behave as an effective immunosupressor in refractory AIHA despite the cause of this autoantibody mediated disease as it can be seen in other analyses [22, 23] .
Rituximab induced rapid responses, most of which took place between the first and third week of infusion. The early response obtained could be attributed to rituximab since a temporal relationship between rituximab infusion and response has been noted. Moreover, these responses seemed to be unaffected by the fact that 86% of patients received other drugs together with rituximab, mainly, corticosteroids, therefore suggesting that rituximab could be the main factor responsible for the therapeutic benefit. Reported therapeutic mechanisms of rituximab include antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis signaling that alter B-cell homeostasis and disturb T-cell activation [24, 25] . Although the mechanism of action of rituximab may be related to depletion of autoreactive B cells, early responses in our study could suggest a saturation of Fc receptors of the monocytemacrophage system by opsonized B cells as an additional mechanism preventing the immune-mediated destruction of the autoantibody coated erythrocyte as previously described [13] .
We have found that the response rate in patients treated with rituximab in combination with other therapies was not different from that shown in patients with rituximab therapy alone. However, in patients with underlying LDs in particular, treatment with a combination of rituximab and other agents may offer additional benefits [11, 13] . Our findings demonstrate that administration of rituximab along with cyclophosphamide and steroids in patients with AIHA and underlying LDs may result in an optimal approach with an effective and durable inmmunosuppresive response without significant toxicity. Accordingly, it has been reported that rituximab, cyclophosphamide, and steroids combination is very effective in treating immune cytopenic diseases (ITP, AIHA) associated with chronic linfoproliferative syndromes [10, 13] .
The optimal rituximab dosing scheme in autoimmune diseases has not been established. In all reported series, the typical dosing regimen for refractory AIHA patients is a weekly dose of 375 mg/m 2 of rituximab for 2 or 4 weeks [2] . In our series, most of patients received four doses of rituximab and seven patients received between one and between doses of rituximab without clear differences in their responses.
Rituximab may probably be less effective in patients previously treated for long periods of time with different immunosuppressive drugs, besides causing damage in these heavily treated patients [26] . Nevertheless, our results indicate that rituximab could induce excellent responses even in heavily treated refractory AIHA patients, and accordingly, this agent could be a fine option as a second line of therapy before splenectomy.
Treatment toxicity was minimal in our study, and no infectious processes were reported. None of the patients developed neutropenia. In similar studies, the doses of rituximab used in the present analysis were also well tolerated [27, 28] . Rituximab has demonstrated a wellestablished safety profile through its use in hematooncological indications for over 10 years [29] , and it has been used for treatment of AD in children, adolescents, and old patients with a good tolerability [11, 28, 30] . However, minor treatable infections have been common in patients with B-cell depletion, whereas severe infections occurred in a small minority [29] . In a recent review [31] regarding the use the rituximab in AD, an incidence of serious infections of 12.5% was reported. In AIHA patients (5 studies, 76 patients), 5 serious infections were reported and 2 patients died of septicemia. The frequency of infections in patients with AD treated with rituximab depends on several factors. Therefore, concomitant immunosuppresive therapies (Tcell immunosuppressive agents), which also enhance or contribute to susceptibility to infection, age of patient, and the presence of other medical problems, have been involved. Rituximab has been associated with viral infections including hepatitis B, cytomegalovirus, herpes simplex virus, varicella zoster virus, West Nile virus, and JC virus [32] . Recently, 57 patients with progressive multifocal leucoencephalopathy after rituximab treatment have been reported [33] . Fifty-two patients suffered from LD and 5 patients had AD. One patient with AIHA developed progressive multifocal leucoencephalopathy after treatment with corticosteroids and rituximab.
In conclusion, rituximab induces a clinical effect not seen with other therapies in AIHA patients refractory to several treatments with little or tolerable associated toxicity. Therefore, this therapy should be considered as a potential early treatment that may achieve a rapid and MR in this subset of patients. Achievement of CR must be the therapeutic objective of rituximab in these patients. Furthermore, we could consider a negative Coombs test after treatment as a predictor of maintenance of response. The clinical effect of rituximab and its minimal toxicity could reduce the need for immunosuppressive agents avoiding their cytotoxic effects. Due to the excellent responses associated to rituximab in combination with cyclophosphamide and steroids, this therapy should be considered as a potential treatment of AIHA associated to LD. Additional large studies are required to answer key questions regarding dosage of rituximab, its optimal position in the therapeutic armamentarium of AIHA, and the role of retreatment and combination therapy in order to enhance its therapeutical effect and duration of response.
